Abstract
Objectives To identify COVID-19 outbreaks and border control failures associated with quarantine systems in Australia and New Zealand and to estimate the failure risks.
Design, setting, participants Observational epidemiological study of travellers transiting quarantine in Australia and New Zealand up to 31 March 2021.
Main outcome measures The incidence of COVID-19 related failures arising from quarantine, and the failure risk for those transiting quarantine, estimated both per 100,000 travellers and per 1000 SARS-CoV-2 positive cases.
Results Australia and New Zealand had 24 COVID-19 related failures arising from quarantine systems up to 31 March 2021 (14 and 10, respectively). One resultant outbreak involved an estimated 800 deaths and quarantine failures instigated nine lockdowns. The failure risk for those transiting quarantine was estimated at 6.3 failures per 100,000 travellers and 5.8 failures (95%CI: 3.5 to 8.1) per 1000 SARS-CoV-2 positive cases. The latter risk was three-fold higher in New Zealand compared with Australia. Approximately 55% of quarantine system failures could likely have been prevented with the full vaccination of frontline border workers, for 70% effectiveness at preventing transmission.
Conclusions Quarantine system failures can be costly in terms of lives and economic impacts such as lockdowns. Ongoing improvements or alternatives to hotel-based quarantine are required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Prof Baker and Dr Kvalsvig received funding support from the Health Research Council of New Zealand (20/1066). Dr Grout, Ms Katar, Dr Ait Ouakrim, Dr Summers, Prof Blakely, and Prof Wilson did not have external funding support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There was no requirement for ethics review as the study only utilised publicly available anonymised data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.